peptidesinstitute.org
HORMONAL

Octreotide

Octreotide (Synthetic Somatostatin Analog)

Synthetic Somatostatin Analog for Hormonal Health

Buy Octreotide
Based on the combined works of Dr. William A. Seeds and Dr. Ian W. Hamley
— authoritative voices whose published research informed this article

The information on this page is compiled from peer-reviewed research and is provided for educational and research purposes only. It is not medical advice, a diagnosis, or a treatment recommendation. Peptides discussed here may not be approved for human use in your jurisdiction. Always consult a qualified healthcare provider before starting, stopping, or modifying any health protocol.

Overview

What is Octreotide?

Octreotide is a synthetic octapeptide analog of somatostatin, the endogenous hypothalamic hormone that broadly inhibits the secretion of multiple other hormones throughout the body. The natural somatostatin molecule has a half-life of only 1-3 minutes in circulation, making it impractical for therapeutic use. Octreotide was engineered to be pharmacologically equivalent to somatostatin while achieving a half-life of approximately 1.7 hours (immediate-release) or weeks (depot formulation) [1], enabling effective hormonal management in clinical settings.

Octreotide binds with high affinity to somatostatin receptor subtype 2 (SSTR2) and with lesser affinity to SSTR3 and SSTR5. This receptor binding profile closely mirrors natural somatostatin activity and produces inhibition of a wide range of secretory hormones: growth hormone (GH), glucagon, insulin, gastrin, cholecystokinin, secretin, vasoactive intestinal peptide (VIP), thyroid-stimulating hormone (TSH), and pancreatic polypeptide. It also reduces intestinal fluid secretion, slows gastrointestinal motility, and inhibits gallbladder contraction.

FDA-approved indications include acromegaly (excess GH secretion from a pituitary adenoma), carcinoid syndrome associated with metastatic carcinoid tumors, and symptoms from vasoactive intestinal peptide-secreting tumors (VIPomas). In acromegaly, octreotide suppresses GH secretion and reduces circulating insulin-like growth factor-1 (IGF-1) levels [3]. Long-term treatment can stabilize and sometimes reduce pituitary tumor volume.

Beyond approved uses, octreotide is investigated in off-label contexts including prevention of post-operative pancreatic complications, management of gastrointestinal bleeding from portal hypertension, treatment of dumping syndrome, and as a component of peptide receptor radionuclide therapy (PRRT) protocols for neuroendocrine tumors. It has the longest-established efficacy and safety profile within the somatostatin analog class.

Research Supply

Source high-purity Octreotide for your research

Buy Octreotide
Protocol

Dosage Guide

Route: Subcutaneous injection (immediate-release) or intramuscular depot injection

Dosing Schedule

PeriodDose
Acromegaly (starting)50 mcg three times daily (TID) subcutaneous; titrate to 100-250 mcg TID over 2-4 weeks
Carcinoid/VIPoma100-600 mcg/day in 2-4 divided doses; 150 mcg TID median maintenance
Maximum reported (divided doses)Up to 1,500 mcg/24 hours with monitoring
Sandostatin LAR depot 10 mg10 mg IM every 28 days
Sandostatin LAR depot 20 mg20 mg IM every 28 days
Sandostatin LAR depot 30 mg30 mg IM every 28 days

Reconstitution

VIAL SIZEPre-filled solutions available at 50 mcg/mL, 100 mcg/mL, and 500 mcg/mL
WATER VOLUMENo reconstitution required for pre-filled immediate-release formulations
CONCENTRATION50, 100, or 500 mcg/mL (immediate-release)
Dose determined by concentration and injection volume

Injection Volumes

DoseVolumeSyringe Units

Administration Tips

  • Warm immediate-release solution to room temperature before injection to reduce discomfort
  • Inject subcutaneously; rotate sites to minimize lipodystrophy
  • The depot formulation must be administered by a healthcare professional into the gluteal muscle
  • Avoid inadvertent IV or subcutaneous administration of the depot suspension
  • Establish clinical response and tolerability with immediate-release before transitioning to depot formulation
Safety

Risks & Side Effects

Commonly Reported

Nausea (most common, particularly at initiation)Diarrhea or loose stoolsAbdominal cramping and flatulenceConstipation (with longer-term use)Injection site pain, redness, or swellingHeadacheDizzinessFatigue

Serious Risks

Gallstones (cholelithiasis)

Octreotide reduces gallbladder contractility, leading to bile stasis and stone formation. Prevalence increases significantly with chronic use. Monitor with ultrasound periodically.

Hypoglycemia or hyperglycemia

Octreotide suppresses both insulin and glucagon; the net glycemic effect is variable and requires monitoring, particularly in diabetic patients.

Bradycardia and conduction abnormalities

QT prolongation risk; monitor with ECG in at-risk patients.

Hypothyroidism

Risk increases with long-term use due to TSH suppression.

Pancreatitis

Rare, reported with somatostatin analog class.

Cardiac valve disorders

Documented more prominently with lanreotide; data for octreotide limited but warrants monitoring with long-term use.

Related Research

Related Peptides

Expert Voices

Experts Covering Octreotide

Dr. William A. Seeds

MD -- Regenerative Medicine Pioneer

Dr. Ian W. Hamley

Diamond Professor of Physical Chemistry -- University of Reading

LEGAL DISCLAIMER

The information provided on this page is for educational and informational purposes only and is not intended as medical advice. Octreotide is FDA-approved for specific indications including acromegaly and carcinoid tumors; all other uses described here are investigational or off-label. Always consult with a qualified healthcare professional before starting any peptide therapy. Individual results may vary. Peptides Institute is not responsible for any adverse effects resulting from the use of information provided on this site.

Frequently Asked Questions

What is Octreotide and what is it used for?
Octreotide is a synthetic somatostatin analog FDA-approved for acromegaly, carcinoid syndrome, and VIPomas. It broadly inhibits growth hormone, glucagon, insulin, and multiple gut hormones by binding somatostatin receptors SSTR2, SSTR3, and SSTR5 with a half-life of 1.7 hours for immediate-release formulation.
How does Octreotide treat acromegaly?
Octreotide suppresses GH secretion from pituitary adenomas and reduces circulating IGF-1 levels by activating somatostatin receptors. Long-term treatment can stabilize and sometimes reduce pituitary tumor volume. Starting doses are 50 mcg three times daily, titrated to 100 to 250 mcg three times daily.
What is the difference between Sandostatin and Sandostatin LAR?
Sandostatin is the immediate-release injectable form requiring two to four daily subcutaneous injections. Sandostatin LAR is a long-acting depot formulation given once every 28 days by intramuscular injection at 10, 20, or 30 mg doses. Patients typically start on immediate-release to establish tolerability before switching.
What are Octreotide side effects?
Common effects include nausea, diarrhea, abdominal cramping, constipation, injection site reactions, headache, and fatigue. The most significant long-term concern is gallstone formation from reduced gallbladder contractility, with prevalence increasing significantly during chronic use. Periodic ultrasound monitoring is recommended.
Does Octreotide cause gallstones?
Yes. Octreotide reduces gallbladder contractility, leading to bile stasis and stone formation. Gallstone prevalence increases significantly with chronic use, making periodic gallbladder ultrasound monitoring an important part of long-term octreotide therapy. This is the most clinically relevant long-term adverse effect.
Can Octreotide affect blood sugar?
Yes. Octreotide suppresses both insulin and glucagon, and the net glycemic effect is variable. It may cause either hypoglycemia or hyperglycemia depending on individual physiology and concurrent medications. Blood glucose monitoring is essential, particularly in diabetic patients or those on glucose-lowering medications.

References

  1. Lamberts SWJ, van der Lely AJ, de Herder WW, et al.. Octreotide. N Engl J Med. 1996. PMID 8532003
  2. Rinke A, Muller HH, Schade-Brittinger C, et al.. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009. PMID 19704057
  3. Ezzat S, Snyder PJ, Young WF, et al.. Octreotide treatment of acromegaly. A randomized, multicenter study. Ann Intern Med. 1992. PMID 1416572

Regulatory & Official Sources